Patents by Inventor Hengyuan Lang

Hengyuan Lang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8580838
    Abstract: Provided are 5-membered heterocycle-based p38 kinase inhibitors. Further provided are pyrazole and imidazole-based p38 kinase, including p38?, and p38? kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: November 12, 2013
    Assignee: Novartis AG
    Inventors: Hengyuan Lang, Olga M. Fryszman, Edcon Chang, Jiong Lan, Yunfeng Fang
  • Patent number: 8410160
    Abstract: Provided are 5-membered heterocycle-based p38 kinase inhibitors. Further provided are pyrazole and imidazole-based p38 kinase, including p38?, and p38? kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: April 2, 2013
    Assignee: Novartis AG
    Inventors: Olga M. Fryszman, Hengyuan Lang, Jiong Lan, Edcon Chang, Yunfeng Fang
  • Publication number: 20120264801
    Abstract: Provided are 5-membered heterocycle-based p38 kinase inhibitors. Further provided are pyrazole and imidazole-based p38 kinase, including p38?, and p38? kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders.
    Type: Application
    Filed: June 22, 2012
    Publication date: October 18, 2012
    Applicant: NOVARTIS AG
    Inventors: Olga M. FRYSZMAN, Hengyuan LANG, Jiong LAN, Edcon CHANG, Yunfeng FANG
  • Patent number: 8242117
    Abstract: Provided are 5-membered heterocycle-based p38 kinase inhibitors. Further provided are pyrazole and imidazole-based p38 kinase, including p38? and p38? kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders.
    Type: Grant
    Filed: November 19, 2010
    Date of Patent: August 14, 2012
    Assignee: Novartis AG
    Inventors: Olga M. Fryszman, Hengyuan Lang, Jiong Lan, Edcon Chang, Yunfeng Fang
  • Publication number: 20120183660
    Abstract: The present invention provides isomannide derivatives having structural formula (I) as shown below and certain subgenera or species thereof, as flavoring agents or tastants, flavor or taste modifiers, and/or flavor/taste enhancers, particularly, savory (“umami”) flavoring agent or tastant, savory taste modifiers, and/or savory flavor enhancers, for ingestible compositions. The present invention also provides methods of preparing isomannide derivatives having the structural formula (II) shown below and certain subgenera or species thereof.
    Type: Application
    Filed: June 30, 2010
    Publication date: July 19, 2012
    Applicant: Senomyx, Inc.
    Inventors: Catherine Tachdjian, Sara L. Adamski-Werner, Jeffrey M. Yamamoto, Hengyuan Lang, Donald S. Karanewsky
  • Publication number: 20110071152
    Abstract: Provided are 5-membered heterocycle-based p38 kinase inhibitors. Further provided are pyrazole and imidazole-based p38 kinase, including p38? and p38? kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders.
    Type: Application
    Filed: November 19, 2010
    Publication date: March 24, 2011
    Inventors: Olga M. FRYSZMAN, Hengyuan LANG, Jiong LAN, Edcon CHANG, Yunfeng FANG
  • Patent number: 7863314
    Abstract: Provided are 5-membered heterocycle-based p38 kinase inhibitors. Further provided are pyrazole and imidazole-based p38 kinase, including p38? and p38? kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders.
    Type: Grant
    Filed: June 25, 2004
    Date of Patent: January 4, 2011
    Assignee: Novartis AG
    Inventors: Olga M. Fryszman, Hengyuan Lang, Jiong Lan, Edcon Chang, Yunfeng Fang
  • Patent number: 7825256
    Abstract: The present invention relates to compounds and methods useful as inhibitors of nitric oxide synthase. Certain compounds of the subject invention have the following structural formula: wherein T, X, and Y are independently selected from the group consisting of CR4, N, NR4, S, and O; U is selected from the group consisting of CR10 and N; V is selected from the group consisting of CR4 and N; W and W? are independently selected from the group consisting of CH2, CR7R8, NR9, O, N(O), S(O)q and C(O); n, m and p are independently an integer from 0 to 5; q is 0, 1, or 2; and other substituents are as defined herein. Other compounds of the subject invention have structural formulas as defined herein. Also disclosed herein are pharmaceutical compositions comprising the compounds of the subject invention.
    Type: Grant
    Filed: November 28, 2005
    Date of Patent: November 2, 2010
    Assignee: Kalypsys, Inc.
    Inventors: Timothy C. Gahman, Hengyuan Lang, Mark R. Herbert, Angelina M. Thayer, Christian A. Hassig, Stewart A. Noble, Russell D. Cousins, Hui Zhuang, Christopher R. Santos, Xiaohong Chen
  • Publication number: 20100234404
    Abstract: Compounds and compositions for modulating the activity of p38 kinases are provided, including p38?, and p38? kinase. Methods for treating, preventing or ameliorating one or more symptoms of a p38 kinase mediated disease or disorder are also provided.
    Type: Application
    Filed: May 28, 2010
    Publication date: September 16, 2010
    Inventors: Hengyuan Lang, Jiong Lan, Yungeng Fang
  • Patent number: 7754726
    Abstract: Benzamide combounds of Formula I: and their compositions for modulating the activity of p38 kinases are provided, including p38?, and p38? kinase. Methods for treating, preventing or ameliorating one or more symptoms of a p38 kinase mediated disease or disorder such as inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, angiogenic disorders, infectious diseases, neurodegenerative diseases, and viral diseases are also provided.
    Type: Grant
    Filed: July 23, 2004
    Date of Patent: July 13, 2010
    Assignee: Novartis AG
    Inventors: Hengyuan Lang, Jiong Lan, Yunfeng Fang
  • Patent number: 7700622
    Abstract: Compounds and compositions for modulating the activity of p38 kinases are provided, including p38? and p38? kinase. Methods for treating, preventing or ameliorating one or more symptoms of a p38 kinase mediated disease or disorder are also provided.
    Type: Grant
    Filed: July 23, 2004
    Date of Patent: April 20, 2010
    Assignee: Novartis AG
    Inventors: Hengyuan Lang, Jiong Lan, Yunfeng Fang
  • Publication number: 20100094021
    Abstract: The present invention discloses a novel method for preparing 3-imidazol-1-yl-[1,2,4]thiadiazole derivatives, particularly to a method of preparing 5-halo-3-imidazol-1-yl-[1,2,4]thiadiazole, more particularly (3-imidazol-1-yl-[1,2,4]thiadiazol-5-yl)-dialkyl-amines, that afford a high yield of pure product.
    Type: Application
    Filed: December 11, 2009
    Publication date: April 15, 2010
    Applicant: KALYPSYS, INC.
    Inventors: Mark R. Herbert, Russell D. Cousins, Hengyuan Lang, Timothy C. Gahman, Stewart A. Noble
  • Publication number: 20090264409
    Abstract: Provided are bicyclic heterocycle-based p38 kinase, including p38? and p38? kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders.
    Type: Application
    Filed: June 25, 2009
    Publication date: October 22, 2009
    Inventors: Qing Dong, Jianqiang Wang, Hengyuan Lang, Jiong Lan
  • Publication number: 20090209536
    Abstract: The present invention relates to compounds and methods useful as modulators of CB2 for the treatment or prevention of disease states including, but not limited to pain, autoimmune disease, malabsorption syndrome, pulmonary disease, osteoporosis, muscle spasm in cancer, neuromuscular disorder, and atherosclerosis progression.
    Type: Application
    Filed: June 16, 2008
    Publication date: August 20, 2009
    Applicant: KALYPSYS, INC.
    Inventors: Timothy Gahman, David Thomas, Hengyuan Lang, Mark Eben Massari
  • Patent number: 7569571
    Abstract: Provided are bicyclic heterocycle-based p38 kinase, including p38? and p38? kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders.
    Type: Grant
    Filed: December 23, 2004
    Date of Patent: August 4, 2009
    Assignee: Novartis AG
    Inventors: Qing Dong, Jianqiang Wang, Hengyuan Lang, Jiong Lan
  • Publication number: 20090062253
    Abstract: The present invention relates to compounds and methods useful as modulators of CB2 for the treatment or prevention of disease states including, but not limited to pain, autoimmune disease, malabsorption syndrome, pulmonary disease, osteoporosis, muscle spasm in cancer, neuromuscular disorder, and atherosclerosis progression.
    Type: Application
    Filed: August 28, 2008
    Publication date: March 5, 2009
    Applicant: KALYPSYS, INC.
    Inventors: Timothy C. Gahman, Cunxiang Zhao, Hengyuan Lang, Mark Eben Massari
  • Publication number: 20070155764
    Abstract: The present invention relates to compounds and methods useful as inhibitors of protein kinases, including B-Raf and several receptor tyrosine and cytoplasmic tyrosine kinases. The present invention is directed to new substituted pyrimidinyloxy urea compounds of Formulas II, III and IV and compositions and their application as pharmaceuticals for the treatment of disease. Methods of modulating of protein kinase activity in a human or animal subject are also provided for the treatment diseases such as cancers.
    Type: Application
    Filed: December 22, 2006
    Publication date: July 5, 2007
    Applicant: KALYPSYS, INC.
    Inventors: Hengyuan Lang, Timothy Gahman, Mark Herbert, Paul Wash, Cunxiang Zhao, Robert Davis
  • Publication number: 20070155746
    Abstract: The present invention relates to compounds and methods useful as inhibitors of protein kinases, including B-Raf and several receptor tyrosine and cytoplasmic tyrosine kinases. The present invention is directed to new substituted pyrimidinyloxy urea compounds of Formulas II, III and IV and compositions and their application as pharmaceuticals for the treatment of disease. Methods of modulating of protein kinase activity in a human or animal subject are also provided for the treatment diseases such as cancers.
    Type: Application
    Filed: December 22, 2006
    Publication date: July 5, 2007
    Applicant: KALYPSYS, INC.
    Inventors: Hengyuan Lang, Timothy Gahman, Mark Herbert, Paul Wash, Cunxiang Zhao, Robert Davis
  • Publication number: 20070142405
    Abstract: Provided are bicyclic heterocycle-based p38 kinase, including p38? and p38? kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders.
    Type: Application
    Filed: December 23, 2004
    Publication date: June 21, 2007
    Inventors: Qing Dong, Jianqiang Wang, Hengyuan Lang, Jiong Lan
  • Publication number: 20070123572
    Abstract: The present invention discloses a novel method for preparing 3-imidazol-1-yl-[1,2,4]thiadiazole derivatives, particularly to a method of preparing 5-halo-3-imidazol-1-yl-[1,2,4]thiadiazole, more particularly (3 -imidazol-1-yl-[1,2,4]thiadiazol-5-yl)-dialkyl-amines, that afford a high yield of pure product.
    Type: Application
    Filed: November 25, 2006
    Publication date: May 31, 2007
    Applicant: KALYPSYS, INC.
    Inventors: Mark Herbert, Russell Cousins, Hengyuan Lang, Timothy Gahman, Stewart Noble